---
title: "Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: Product information and disease description"
description: "Formulary evidence on Lonvoguran ziclumeran (lonvo-z, NTLA-2002) in Hereditary angioedema: Product information and disease description. Covers Product description and Place of product in therapy. 66 evidence topics quoted from 49 sources."
canonical: "https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/product-information-and-disease-description"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Investigational status

> “Lonvo-z is an investigational product that has not been approved by FDA or any Health Authority. Its efficacy and safety have not been established.”

Source: [Intellia Therapeutics presentation (2026)](https://ir.intelliatx.com/node/12426/html)

<a id="topic-2.1.1-2"></a>

##### Regulatory status: Under review; Rolling BLA initiated April 2026 and accepted September 2026

> “initiated a rolling submission of a biologics license application (BLA)”

Source: [Intellia Therapeutics rolling BLA submission announcement (2026)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-initiates-rolling-submission-biologics)

> “In April 2026, we announced the initiation of a rolling biologics license application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) for lonvo-z.”

Source: [Intellia Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1652130/000119312526337952/ntla-20260630.htm)

> “Sept. 08, 2026 (GLOBE NEWSWIRE)”
> “has accepted the Biologics License Application (BLA) for lonvo-z”

Source: [Intellia Therapeutics BLA acceptance announcement (2026)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-fda-acceptance-biologics-license)

<a id="topic-2.1.1-3"></a>

##### FDA acceptance, review designation, target action date, and advisory committee

> “accepted the Biologics License Application (BLA)”
> “Priority Review”
> “PDUFA target action date of March 10, 2027”
> “not currently planning to hold an advisory committee”

Source: [Intellia Therapeutics BLA acceptance announcement (2026)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-fda-acceptance-biologics-license)

<a id="topic-2.1.1-4"></a>

##### Launch: Anticipated in the first quarter of 2027

> “Intellia significantly advanced its launch readiness in recent months, completing the deployment of its field organization and deepening its engagement with HAE treatment centers and payers in preparation for a planned commercial launch in the first quarter of 2027.”

Source: [Intellia Therapeutics third quarter 2026 results (2026)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-third-quarter-2026-financial)

<a id="topic-2.1.1-5"></a>

##### FDA orphan drug designation

> “has granted orphan drug designation for Intellia’s in vivo CRISPR/Cas9 genome editing candidate, NTLA-2002”

Source: [Intellia Therapeutics (2022)](https://www.globenewswire.com/news-release/2022/09/01/2508902/0/en/Intellia-Therapeutics-Receives-U-S-FDA-Orphan-Drug-Designation-for-NTLA-2002-an-Investigational-CRISPR-Therapy-for-the-Treatment-of-Hereditary-Angioedema.html)

<a id="topic-2.1.1-6"></a>

##### FDA Regenerative Medicine Advanced Therapy designation

> “granted Regenerative Medicine Advanced Therapy (RMAT) designation to NTLA-2002 for the treatment of hereditary angioedema (HAE).”

Source: [Intellia Therapeutics (2023)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-fda-regenerative-medicine)

<a id="topic-2.1.1-7"></a>

##### Additional international regulatory designations: European Union

> “orphan designation in the European Union”

Source: [Intellia Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm)

<a id="topic-2.1.1-8"></a>

##### Additional international regulatory designations: United Kingdom

> “Innovation Passport”

Source: [Intellia Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm)

<a id="topic-2.1.1-9"></a>

##### Additional international regulatory designations: European Medicines Agency

> “Priority Medicine (“PRIME”) program”

Source: [Intellia Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm)

<a id="topic-2.1.1-10"></a>

##### Reviews and editorial publications: kallikrein inhibitors in preclinical and early phase studies

> “Lastly, NTLA-2002 is an investigational gene-editing therapy.”

Source: [Farkas and Balla (2024)](https://pubmed.ncbi.nlm.nih.gov/38366937/)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: Intellia Therapeutics

> “Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for lonvo-z”

Source: [Intellia Therapeutics BLA acceptance announcement (2026)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-fda-acceptance-biologics-license)

<a id="topic-2.1.2.1-2"></a>

###### Manufacturer and product name

> “Intellia Therapeutics”
> “lonvoguran ziclumeran (“lonvo-z,” also referred to as NTLA-2002)”

Source: [Intellia Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Investigational formulation

> “NTLA-2002 comprises LP01 (ionizable lipid), additional lipids and two RNA drug substances.”

Source: [Longhurst et al. (2023)](https://www.intelliatx.com/wp-content/uploads/Longhurst_H_C1INH_06.05.2023_Transient-exposure-to-NTLA-2002-an-investigational-CRISPR_CAS9-based-gene-editing-therapy-leads-to-durable-PD-responses-and-attack-control-in-HAE-vf.pdf)

<a id="topic-2.1.2.2-2"></a>

###### Material safety data sheet

No evidence found.

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

<a id="topic-2.1.2.3-1"></a>

###### Average sales price and wholesale acquisition cost

Not applicable.

<a id="topic-2.1.2.3-2"></a>

###### Pricing and contracting

> “finalizing price and contracting strategy for lonvo-z”

Source: [Intellia Therapeutics corporate overview (2026)](https://ir.intelliatx.com/static-files/a57908a6-aaca-404d-9072-32471cd3d41e)

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### Therapeutic modality

> “Gene editing”

Source: [Somatic Cell Gene Editing Consortium NCT05120830](https://scge.mcw.edu/platform/data/report/clinicalTrials/NCT05120830)

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Investigational population in the phase 3 trial supporting the BLA

> “in adults and adolescents aged 16 years and older with Type 1 or Type 2 HAE.”

Source: [Intellia Therapeutics BLA acceptance announcement (2026)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-fda-acceptance-biologics-license)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Ownership, therapeutic class, and proposed mechanism

> “NTLA-2002 is a wholly owned, investigational in vivo CRISPR-based therapy designed to knock out the KLKB1 gene in the liver”

Source: [Intellia Therapeutics (2025)](https://www.sec.gov/Archives/edgar/data/0001652130/000095017025028373/ntla-ex99_1.htm)

<a id="topic-2.1.2.6.1-2"></a>

###### Delivery components

> “lipid nanoparticles”
> “guide RNA”
> “messenger RNA that encodes the Cas9 enzyme”

Source: [Intellia Therapeutics (2022)](https://www.globenewswire.com/news-release/2022/09/01/2508902/0/en/Intellia-Therapeutics-Receives-U-S-FDA-Orphan-Drug-Designation-for-NTLA-2002-an-Investigational-CRISPR-Therapy-for-the-Treatment-of-Hereditary-Angioedema.html)

<a id="topic-2.1.2.6.1-3"></a>

###### Hepatic targeting for novel prophylactic therapies: review

> “This report reviews currently available data on hepatic-focused interventions for HAE that have advanced into human trials.”

Source: [Riedl et al. (2024a)](https://pure.amsterdamumc.nl/en/publications/clinical-progress-in-hepatic-targeting-for-novel-prophylactic-the)

Additional sources: [Pardi and Ivics (2024)](https://pubmed.ncbi.nlm.nih.gov/38925443/)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Phase 2: plasma kallikrein change

| Outcome | NTLA-2002 25 mg | NTLA-2002 50 mg | Placebo |
| --- | --- | --- | --- |
| Plasma kallikrein change from baseline, week 16 | “-55%” | “-86%” | “2%” |

Source: [Intellia Therapeutics investor presentation (2024)](https://www.intelliatx.com/wp-content/uploads/Intellia_NTLA-2002-Phase-2-Data-Investor-Presentation_10.24.24_vF.pdf)

<a id="topic-2.1.2.6.2-2"></a>

###### Phase 3: plasma kallikrein time course

> “reached a steady state by week 5 and remained stable through the data cutoff.”

Source: [Intellia Therapeutics additional HAELO phase 3 results announcement (2026)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-reports-additional-positive-phase-3)

<a id="topic-2.1.2.6.2-3"></a>

###### Preclinical studies: editing durability after partial hepatectomy in huKLKB1 mice

> “KLKB1 editing is retained following partial hepatectomy-induced liver regeneration, further demonstrating the durability of CRISPR/Cas9-induced gene editing with NTLA-2002.”

Source: [Walsh et al. (2022)](https://www.intelliatx.com/wp-content/uploads/AAAAi-Scientific-Poster_01.5_Final.pdf)

<a id="topic-2.1.2.6.2-4"></a>

###### Preclinical studies: KLKB1 gene knockout in nonhuman primates

> “Kallikrein activity reduction sustained for at least 77 weeks in NHPs”

Source: [Intellia Therapeutics AAAAI presentation (2021)](https://www.intelliatx.com/wp-content/uploads/AAAAi_2021_NTLA_HAE_27Feb2021.pdf)

Additional sources: [Luong et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42504735/)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Pharmacokinetics: lipid nanoparticle component exposure and clearance

> “The concentration-time profile of LP01, a representative component of NTLA-2002, demonstrates dose-dependent exposure and rapid clearance”

Source: [Longhurst et al. (2023)](https://www.intelliatx.com/wp-content/uploads/Longhurst_H_C1INH_06.05.2023_Transient-exposure-to-NTLA-2002-an-investigational-CRISPR_CAS9-based-gene-editing-therapy-leads-to-durable-PD-responses-and-attack-control-in-HAE-vf.pdf)

<a id="topic-2.1.2.6.3-2"></a>

###### LP01 plasma half-life

> “Estimated mean t1/2 range, 16.8 – 21.3 h.”

Source: [Longhurst et al. (2023)](https://www.intelliatx.com/wp-content/uploads/Longhurst_H_C1INH_06.05.2023_Transient-exposure-to-NTLA-2002-an-investigational-CRISPR_CAS9-based-gene-editing-therapy-leads-to-durable-PD-responses-and-attack-control-in-HAE-vf.pdf)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

Not applicable.

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

No evidence found.

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Lonvoguran ziclumeran

No evidence found.

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Lonvoguran ziclumeran on Other Drugs

No evidence found.

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Investigational phase 3 dose

> “Patients will be randomized 2:1 to receive a single 50 mg infusion of NTLA-2002 or placebo.”

Source: [Intellia Therapeutics HAELO first patient dosed announcement (2025)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-first-patient-dosed-haelo-phase)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Route and setting of administration

> “one-time IV infusion administered in an outpatient setting”

Source: [Intellia Therapeutics corporate overview (2026)](https://ir.intelliatx.com/static-files/a57908a6-aaca-404d-9072-32471cd3d41e)

<a id="topic-2.1.2.10.2-2"></a>

###### Infusion duration in the phase 1/2 study

> “INFUSED OVER 2-4 HOURS”

Source: [Intellia Therapeutics ACAAI poster (2025)](https://www.intelliatx.com/wp-content/uploads/ACAAI-2025_Lonvo-z-Ph1-2-Safety_Poster_FINAL.pdf)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Planned distribution and treatment-center identification

> “Finalized distribution model for launch”
> “Identified potential treatment centers”

Source: [Intellia Therapeutics corporate overview (2026)](https://ir.intelliatx.com/static-files/a57908a6-aaca-404d-9072-32471cd3d41e)

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### HAELO: withdrawal of long-term prophylaxis

> “Patients on LTP were required to discontinue those therapies in the weeks prior to dosing.”

Source: [Intellia Therapeutics HAELO phase 3 results announcement (2026)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-reports-positive-phase-3-results)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Lonvoguran ziclumeran on Quality Measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Cross-trial comparison limitations

> “Cross-trial comparisons have inherent limitations and should be interpreted with caution.”

Source: [Intellia Therapeutics presentation (2026)](https://ir.intelliatx.com/node/12426/html)

Additional sources: [Walsh et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40434599/)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Inheritance pattern

> “an autosomal dominant pattern”

Source: [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Hereditary angioedema

Additional sources: [Sandberg et al. (2024)](https://medicaljournalssweden.se/actadv/article/view/24176)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Hereditary angioedema

<a id="topic-2.2.1.2.2-1"></a>

###### Epidemiology

> “Hereditary angioedema is estimated to affect 1 in 50,000 people worldwide.”

Source: [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/)

<a id="topic-2.2.1.2.2-2"></a>

###### Prevalence and incidence: systematic literature review

> “Diagnostic methodology varied greatly, with a minority of studies citing an established guideline.”

Source: [Craig et al. (2026)](https://karger.com/iaa/article/doi/10.1159/000553023/953095/Prevalence-and-Incidence-of-Hereditary-Angioedema)

<a id="topic-2.2.1.2.2-3"></a>

###### Pooled diagnosed annual prevalence: combined HAE types and 95% confidence interval

> “1.70 per 100,000 (1.58–1.83; combined types).”

Source: [Craig et al. (2026)](https://karger.com/iaa/article/doi/10.1159/000553023/953095/Prevalence-and-Incidence-of-Hereditary-Angioedema)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Age at symptom onset

> “Symptoms of hereditary angioedema typically begin in childhood and worsen during puberty.”

Source: [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Pathophysiology

> “Hereditary angioedema (HAE) is characterized by C1 esterase inhibitor (C1INH) deficiency, leading to uninhibited kallikrein-kinin system (KKS) activation and bradykinin production resulting in angioedema attacks”

Source: [Kaplan et al. (2026)](https://www.intelliatx.com/wp-content/uploads/AAAAI-2026_KKS-Modeling-Poster_with-Supplement.pdf)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Diagnostic testing

> “Measurements of serum/plasma levels of C1–INH function, C1–INH protein, and C4 are used to diagnose HAE-1/2”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

<a id="topic-2.2.1.5-2"></a>

###### Systematic literature review of HAE disease burden: diagnostic delay

> “The mean or median delay from the first onset of a symptom of HAE to confirmed diagnosis ranged from 3.9 to 26 years.”

Source: [Guan et al. (2024)](https://link.springer.com/article/10.1186/s13023-024-03265-z)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Cutaneous swelling: hands, feet, and face

> “HAE is a very rare and potentially life-threatening genetic condition involving swelling of various parts of the body, hands, feet, or face.”

Source: [US Hereditary Angioedema Association](https://www.haea.org/)

<a id="topic-2.2.1.6-2"></a>

###### Gastrointestinal symptoms: intestinal attacks

> “severe abdominal pain, nausea, and vomiting.”

Source: [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/)

<a id="topic-2.2.1.6-3"></a>

###### Airway symptoms: obstruction risk

> “can restrict breathing and lead to life-threatening obstruction of the airway.”

Source: [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Consequences of abdominal attacks

> “abdominal attacks may lead to unnecessary surgeries or opiate dependence.”

Source: [Henao et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4859422/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Hereditary angioedema

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Burden of disease in adults: multinational survey

> “In the survey, participants reported 11.5 ± 14.2 HAE attacks (mean ± SD) in the past 6 months.”

Source: [Watt et al. (2026)](https://link.springer.com/article/10.1186/s13023-025-04134-z)

<a id="topic-2.2.1.8.1-2"></a>

###### Multinational adult survey: treatment exposure and quality-of-life outcomes

| Measure | Reported result |
| --- | --- |
| Participants included | “260” |
| Participants using any long-term prophylaxis | “153 (58.8%)” |
| First-line prophylaxis among prophylaxis users, per study classification | “56/153 (36.6%)” |
| AE-QoL total score, mean ± SD | “42.9 ± 23.2” |
| Participants with AE-QoL total score ≥39 | “137 of 260 (52.7%)” |
| Moderate to severe anxiety by HADS | “69 (26.5%)” |
| Moderate to severe depression by HADS | “27 (10.4%)” |

Source: [Watt et al. (2026)](https://link.springer.com/article/10.1186/s13023-025-04134-z)

<a id="topic-2.2.1.8.1-3"></a>

###### Patient preferences for long-term prophylaxis: discrete-choice experiment

> “A reduction in attack frequency is the most important treatment feature for adults living with hereditary angioedema.”

Source: [Villa et al. (2026)](https://link.springer.com/article/10.1007/s40271-025-00798-8)

Additional sources: [Busse et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41698689/); [Olson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41429313/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### Drug patterns and economic costs

> “Notably, annualized expenditures for ODT prescriptions, hospitalizations, and ED visits averaged >$200,000, even after initiation of SC LTP.”

Source: [Kutrieb et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13151981/)

Additional sources: [Castaldo et al. (2021)](https://www.researchgate.net/publication/349299347_Assessing_the_cost_and_quality-of-life_impact_of_on-demand-only_medications_for_adults_with_hereditary_angioedema); [Princic et al. (2025)](https://becaris.figshare.com/articles/dataset/Supplementary_materials_Comparison_of_real-world_healthcare_resource_utilization_and_costs_among_patients_with_hereditary_angioedema_on_lanadelumab_or_berotralstat_long-term_prophylaxis/28450706); [Arora et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37558360/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Hereditary angioedema on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Income loss from work missed because of attacks

> “missed work because of acute attacks resulted in an income loss of $3402 annually”

Source: [Guan et al. (2024)](https://link.springer.com/article/10.1186/s13023-024-03265-z)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### Genetic testing: cost and limited routine necessity

> “genetic testing can be costly, time-consuming, and rarely necessary.”

Source: [Henao et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4859422/)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 C1 Esterase Inhibitors

<a id="topic-2.2.2.1.1-1"></a>

###### International/Canadian guideline: first-line long-term prophylaxis options

> “Berotralstat, donidalorsen, garadacimab, lanadelumab, or pdC1INH could be used as first-line therapy for long-term prophylaxis in patients with HAE due to C1INH deficiency.”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Plasma Kallikrein Inhibitors

<a id="topic-2.2.2.1.2-1"></a>

###### Sebetralstat: oral on-demand treatment

> “EKTERLY is a plasma kallikrein inhibitor that is used for the treatment of acute attacks of hereditary angioedema (HAE)”
> “an oral tablet.”

Source: [FDA Drug Trials Snapshots EKTERLY (2025)](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-ekterly)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Bradykinin B2 Receptor Antagonists

<a id="topic-2.2.2.1.3-1"></a>

###### Icatibant: receptor antagonism

> “a specific and selective competitive antagonist of the bradykinin B2 receptor”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Factor XIIa Inhibitors

<a id="topic-2.2.2.1.4-1"></a>

###### Garadacimab: mechanism and maintenance dosing

> “Garadacimab-gxii is an inhibitor of activated FXII”
> “an initial loading dose of 400 mg”
> “200 mg administered subcutaneously every month.”

Source: [FDA ANDEMBRY prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761367s000lbl.pdf)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Prekallikrein-directed Antisense Oligonucleotides

<a id="topic-2.2.2.1.5-1"></a>

###### Donidalorsen: prophylaxis and dosing interval

> “DAWNZERA is a prekallikrein-directed antisense oligonucleotide indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE)”
> “every four or eight weeks.”

Source: [FDA Drug Trials Snapshots DAWNZERA (2025)](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-dawnzera)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Attenuated Androgens

<a id="topic-2.2.2.1.6-1"></a>

###### Second-line long-term prophylaxis

> “We recommend the use of androgens only as second-line long-term prophylaxis.”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Antifibrinolytics

<a id="topic-2.2.2.1.7-1"></a>

###### Tranexamic acid: reported prophylactic responses in HAE-FXII, HAE-PLG, and HAE with normal C1 inhibitor of unknown cause

> “have shown favourable responses to LTP, particularly with tranexamic acid.”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

<a id="topic-2.2.2.1.7-2"></a>

###### Androgens and antifibrinolytics: restriction on first-line use

> “no longer recommended as first-line options”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

<a id="heading-2.2.2.1.8"></a>

###### 2.2.2.1.8 Plasma Replacement

<a id="topic-2.2.2.1.8-1"></a>

###### Fresh frozen plasma: fallback for on-demand treatment

> “treat HAE attacks if none of the FDA-approved on-demand medications are available.”

Source: [Busse et al. (2021)](https://www.haea.org/assets/img/TreatmentGuidelines040321.pdf)

<a id="heading-2.2.2.1.9"></a>

###### 2.2.2.1.9 Progestins

<a id="topic-2.2.2.1.9-1"></a>

###### Progestin prophylaxis: variant-specific observational evidence

| Feature | Guideline description |
| --- | --- |
| Subtype with reported responses | “HAE-FXII” |
| Reported response | “Favourable responses” |
| Evidence for other variants | “limited evidence for other HAE-nC1INH variants.” |

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

<a id="heading-2.2.2.1.10"></a>

###### 2.2.2.1.10 Supportive Care and Airway Management

<a id="topic-2.2.2.1.10-1"></a>

###### Supportive care when effective on-demand treatment is not available

> “IV fluids, antiemetics, narcotic pain medication, or intubation”

Source: [Busse et al. (2021)](https://www.haea.org/assets/img/TreatmentGuidelines040321.pdf)

<a id="heading-2.2.2.1.11"></a>

###### 2.2.2.1.11 Limitations of Current Therapies

<a id="topic-2.2.2.1.11-1"></a>

###### Summary

The multinational adult survey reported a mean of 11.5 attacks over six months, but only 56 of 153 participants using prophylaxis reported a first-line option under the study classification. These findings should not be interpreted as a failure rate for current first-line prophylaxis or as a controlled comparison of drugs. A claims study reported annualized expenditure above $200,000 for on-demand prescriptions, hospitalizations, and emergency department visits even after subcutaneous prophylaxis began. The Cochrane review identified limitations in drawing conclusions about relative efficacy because head-to-head trials were lacking.

Source: [Watt et al. (2026)](https://link.springer.com/article/10.1186/s13023-025-04134-z); [Kutrieb et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13151981/); [Beard et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9632406/)

<a id="topic-2.2.2.1.11-2"></a>

###### Long-term prevention of attacks: Cochrane review

> “This and the lack of head‐to‐head trials prevented us from drawing firm conclusions on the relative efficacy of the drugs.”

Source: [Beard et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9632406/)

Additional sources: [Zuraw et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40300843/)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary

The trial supporting the accepted BLA permitted enrollment of adults and adolescents aged 16 years or older with type 1 or type 2 HAE. The investigational regimen is a single 50-mg intravenous infusion, with outpatient administration anticipated. HAELO required discontinuation of long-term prophylaxis before dosing, so its placebo-controlled findings should not be interpreted as an active-comparator trial or as evidence for routine combination with ongoing prophylaxis. The investigational regimen does not replace the guideline requirement for rapid access to on-demand treatment.

Source: [Intellia Therapeutics BLA acceptance announcement (2026)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-fda-acceptance-biologics-license); [Intellia Therapeutics HAELO first patient dosed announcement (2025)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-first-patient-dosed-haelo-phase); [Intellia Therapeutics corporate overview (2026)](https://ir.intelliatx.com/static-files/a57908a6-aaca-404d-9072-32471cd3d41e); [Intellia Therapeutics HAELO phase 3 results announcement (2026)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-reports-positive-phase-3-results); [Busse et al. (2021)](https://www.haea.org/assets/img/TreatmentGuidelines040321.pdf)

Additional sources: [Uminski et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12618362/)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### HAELO: sponsor-reported subgroup findings

> “meaningful attack-rate reductions were observed for all evaluated subgroups”

Source: [Intellia Therapeutics additional HAELO phase 3 results announcement (2026)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-reports-additional-positive-phase-3)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### US HAEA Medical Advisory Board guidelines: on-demand medication access

> “Effective treatment of HAE requires that all patients have rapid access to effective on-demand medications.”

Source: [Busse et al. (2021)](https://www.haea.org/assets/img/TreatmentGuidelines040321.pdf)

Additional sources: [Vázquez et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42165046/)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### HAELO: observed monthly attack rate during weeks 5–28

> “a mean monthly attack rate of 0.26 in the lonvo-z arm compared with 2.10 in the placebo arm (p<0.0001).”

Source: [Intellia Therapeutics HAELO phase 3 results announcement (2026)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-reports-positive-phase-3-results)

## Related pages
- [Lonvoguran ziclumeran (lonvo-z): Hereditary angioedema](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema) · [Markdown](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema.md)
- [Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: Terms and abbreviations](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/terms-and-abbreviations.md)
- [Lonvoguran ziclumeran (lonvo-z): Hereditary angioedema](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/executive-summary.md)
- [Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: Clinical evidence](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/clinical-evidence.md)
- [Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: Economic information and modeling report](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/economics) · [Markdown](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/economics.md)
- [Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: References](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/references) · [Markdown](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/references.md)
- [Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: prevalence by geography](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/prevalence) · [Markdown](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/prevalence.md)
- [Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/cost-effectiveness-analyses.md)
